文献速递精神分裂症与精神病性障碍心境障碍儿童青少年精神

青少年致幻剂使用与精神病性或躁狂症状的关联

Adolescent Psychedelic Use and Psychotic or Manic Symptoms.
PubMed 文献 · JAMA Psychiatry · 2024-01-01

调整其他药物使用后,致幻剂使用与精神病性症状降低相关,但与躁狂症状的关联受精神分裂症或双相 I 型障碍遗传易感性修饰。

要点

  • 调整药物使用后,致幻剂使用与青少年精神病性症状降低相关。
  • 致幻剂使用与躁狂症状的关联受精神分裂症或双相 I 型障碍遗传风险修饰。
  • 多数致幻剂使用者(99%)也报告使用其他药物,结果需谨慎解读。

核心结论

  • 调整其他药物使用后,青少年自然使用致幻剂可能与较低的精神病性症状相关。
  • 致幻剂使用与躁狂症状的关联似乎与精神分裂症或双相 I 型障碍的遗传易感性有关。

研究设计与样本

  • 横断面分析 15 岁时过去致幻剂使用与精神病性或躁狂症状的关联,采用遗传信息设计。

主要发现

  • 541 名参与者报告过去使用致幻剂,其中 535 人(99%)也报告过去使用其他药物。
  • 调整物质特异性药物使用后,致幻剂使用与精神病性症状降低相关(β=-0.79,95%CI -1.18 至 -0.41)。
  • 调整物质聚合药物使用后,致幻剂使用与精神病性症状降低相关(β=-0.39,95%CI -0.50 至 -0.27)。
  • 同胞对照分析中,调整物质特异性药物使用后,致幻剂使用与精神病性症状降低相关(β=-0.89,95%CI -1.61 至 -0.16)。
  • 同胞对照分析中,调整物质聚合药物使用后,致幻剂使用与精神病性症状降低相关(β=-0.24,95%CI -0.48 至 -0.01)。

关键数值与推荐

  • 致幻剂使用与精神分裂症遗传易感性对躁狂症状存在显著交互作用(调整物质特异性药物使用:β=0.17,95%CI 0.01 至 0.32)。
  • 致幻剂使用与精神分裂症遗传易感性对躁狂症状存在显著交互作用(调整物质聚合药物使用:β=0.17,95%CI 0.02 至 0.32)。
  • 致幻剂使用与双相 I 型障碍遗传易感性对躁狂症状存在显著交互作用(调整物质特异性药物使用:β=0.20,95%CI 0.04 至 0.36)。
  • 致幻剂使用与双相 I 型障碍遗传易感性对躁狂症状存在显著交互作用(调整物质聚合药物使用:β=0.17,95%CI 0.01 至 0.33)。

临床怎么用

  • 临床评估青少年致幻剂使用时,应同时评估其他药物使用及精神病性或躁狂症状。
  • 对有精神分裂症或双相 I 型障碍遗传风险的青少年,需关注致幻剂使用与躁狂症状的关联。
  • 解读致幻剂使用与精神病性症状的负向关联时,应结合研究局限性谨慎判断。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: While psychedelic-assisted therapy has shown promise in the treatment of certain psychiatric disorders, little is known about the potential risk of psychotic or manic symptoms following naturalistic psychedelic use, especially among adolescents. OBJECTIVE: To investigate associations between naturalistic psychedelic use and self-reported psychotic or manic symptoms in adolescents using a genetically informative design. DESIGN, SETTING, AND PARTICIPANTS: This study included a large sample of adolescent twins (assessed at age 15, 18, and 24 years) born between July 1992 and December 2005 from the Swedish Twin Registry and cross-sectionally evaluated the associations between past psychedelic use and psychotic or manic symptoms at age 15 years. Individuals were included if they answered questions related to past use of psychedelics. Data were analyzed from October 2022 to November 2023. MAIN OUTCOMES AND MEASURES: Primary outcome measures were self-reported psychotic and manic symptoms at age 15 years. Lifetime use of psychedelics and other drugs was also assessed at the same time point. RESULTS: Among the 16 255 participants included in the analyses, 8889 were female and 7366 were male. Among them, 541 participants reported past use of psychedelics, most of whom (535 of 541 [99%]) also reported past use of other drugs (ie, cannabis, stimulants, sedatives, opioids, inhalants, or performance enhancers). When adjusting for substance-specific and substance-aggregated drug use, psychedelic use was associated with reduced psychotic symptoms in both linear regression analyses (β, -0.79; 95% CI, -1.18 to -0.41 and β, -0.39; 95% CI, -0.50 to -0.27, respectively) and co-twin control analyses (β, -0.89; 95% CI, -1.61 to -0.16 and β, -0.24; 95% CI, -0.48 to -0.01, respectively). In relation to manic symptoms, likewise adjusting for substance-specific and substance-aggregated drug use, statistically significant interactions were found between psychedelic use and genetic vulnerability to schizophrenia (β, 0.17; 95% CI, 0.01 to 0.32 and β, 0.17; 95% CI, 0.02 to 0.32, respectively) or bipolar I disorder (β, 0.20; 95% CI, 0.04 to 0.36 and β, 0.17; 95% CI, 0.01 to 0.33, respectively). CONCLUSIONS AND RELEVANCE: The findings in this study suggest that, after adjusting for other drug use, naturalistic use of psychedelic may be associated with lower rates of psychotic symptoms among adolescents. At the same time, the association between psychedelic use and manic symptoms seems to be associated with genetic vulnerability to schizophrenia or bipolar I disorder. These findings should be considered in light of the study's limitations and should therefore be interpreted with caution.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Simonsson O, Mosing MA, Osika W, et al. Adolescent Psychedelic Use and Psychotic or Manic Symptoms. JAMA Psychiatry. 2024. PMID: 38477889. doi:10.1001/jamapsychiatry.2024.0047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。